Will ViiV’s Regulatory Stance Delay Access To Cabotegravir Despite MPP Deal?
Paxlovid Precedent A Concern
Scrip looks at the contours of MPP’s recent sub-licensing deal for ViiV Healthcare’s cabotegravir with Cipla, Aurobindo and Mylan, along with pricing dynamics and precedents to evaluate a few barriers to access
